Thus, if sapanisertib is to be tested again in ALL, it will be important to administer doses that achieve higher plasma concentrations and, in view of results with mTORC1 inhibitors, to consider administering TORC1/2 inhibitors in conjunction with additional agents. This evidence concerns the gene CRTC1 and acute lymphoblastic leukemia.